Cepravin Dry Cow 250 mg Intramammary suspension pack of 20

Target Species Cattle. Indications for use Recommended for routine dry cow therapy to treat existing sub-clinical infections and to prevent new infections which occur during the dry period. Contraindications Not for use in the lactating cow. Not intended for use within 54 days of calving. Special warnings for each target species No special warnings are considered necessary. Special precautions for use Use of the product should be based on susceptibility testing of the bacteria isolated from milk samples from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to cefalonium and may decrease the effectiveness of treatment with other beta lactams. Dry cow therapy protocols should take local and national policies on antimicrobial use into consideration, and undergo regular veterinary review. The feeding to calves of milk containing residues of cefalonium that could select for antimicrobial-resistant bacteria (e.g. production of beta-lactamases) should be avoided up to the end of the milk withdrawal period, except during the colostral phase. The efficacy of the product has only been established against pathogens sensitive to the active substance. Consequently, serious acute mastitis (potentially fatal) due to other pathogen species, particularly Pseudomonas aeruginosa, can occur after drying off. Good hygiene practices should be thoroughly respected in order to reduce this risk. Do not bend the nozzle. Do not contaminate the nozzle If calving occurs before 54 days after treatment, the absence of antibiotic should be confirmed by testing before the milk is used for human consumption. Milk for human consumption may be taken after 54 days plus 96 hours after treatment. In cows suffering from hypocalcaemia it may be necessary to discard milk for a longer period. If the product is used in heifers during their first pregnancy the same precautions should be observed as in cows, i.e. infusions should be given not less than 54 days before calving and milk discarded for the statutory four days after calving. Summer Mastitis - It is unlikely that antibiotic treatment alone will control Summer Mastitis and therefore other measures should be implemented as part of routine management. These measures include: - Practising some form of fly control on the farm. - Avoiding pasturing cattle on wet or wooded fields which are known to be associated with Summer Mastitis. - Post-infusion teat dipping of cows and heifers receiving prophylactic intramammary infusions for the disease. - Prompt attention to teat injuries or sores as these rapidly attract flies. - Farms with an intractable problem should consider changing the calving pattern to avoid having animals at risk during the summer months. Operator warnings Penicillin and cefalosporins may cause sensitisation (allergy) following injection, inhalation, ingestion or skin contact. Sensitivity to penicillin may lead to cross-sensitivity to cefalosporin and vice versa. Allergic reactions to these substances may occasionally be serious. Do not handle this product if you know you are sensitised, or if you have been advised not to work with such preparations. Handle this product with great care to avoid exposure, taking all recommended precautions. If you develop symptoms following exposure such as a skin rash you should seek medical advice and show the Doctor this warning. Swelling of the face, lips or eyes or difficulty breathing are more serious symptoms and require urgent medical attention. Wash hands after use. Adverse Reactions None known Use during pregnancy or lactation Intended for use during the last trimester of pregnancy once the lactating cow has been dried off. There is no adverse treatment effect on the foetus. Not to be used in cows that are lactating. Interactions There are no known interactions.